Sponsors (55)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Introduced February 24, 2025 by Gus Bilirakis · Last progress February 24, 2025
Creates federal support for regional research centers, studies, training, and demonstration projects to improve detection, prevention, and treatment of rare kidney diseases. The bill authorizes NIDDK Centers of Excellence to fund research, public education, and clinical resources; requires HHS to study testing, precision medicine, and access issues; expands nephrology training and fellowships; and directs CMS experiments and a study to test clinical approaches that delay or avoid dialysis and transplant.
The bill directs modest, targeted federal investment and coordination to improve diagnosis, workforce training, genetic research, and access for people with rare kidney diseases — but its limited funding, potential equity gaps, privacy risks, and possible fiscal or implementation trade-offs may constrain how broadly and quickly those benefits reach affected Americans.
Patients with rare kidney diseases (including those in rural and underserved communities) will gain improved diagnosis, care, and treatment development through new research centers, targeted outreach, and coordinated studies.
People in communities disproportionately affected by kidney disease will have greater access to nephrologists and specialists because of expanded clinical training, fellowships (with stipends), and workforce development.
Hospitals, state governments, and Congress will get coordinated, evidence-based recommendations via cross-agency reports and stakeholder consultations to guide policy and program changes.
Patients, hospitals, and advocacy groups may see limited impact because the authorized funding levels ($6M/yr for centers and $1M/yr for the study) are modest and likely insufficient to build a comprehensive nationwide program.
Rural areas and other non-awarded regions risk being left without services because grant awards could concentrate resources in selected regional centers, producing geographic and access gaps.
Patients (particularly racial and ethnic minorities) face privacy and civil‑liberties risks from collection and analysis of genetic and clinical data (including APOL1) if data protections and limits on use are not specified.